Heparin in Acute Embolic Stroke Trial "HAEST"


Phase 3 Results

Trial Description

To test whether treatment with low molecular weight heparin (LMWH) is superior to aspirin for the prevention of recurrent stroke during the first 14 days.


  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Dalteparin (Fragmin®)Drug
    Other Names: Fragmin
    Intervention Desc: Low molecular weight heparin
  • LMW heparin Drug
    Intervention Desc: Low molecular weight heparin and heparinoids. See also specific compounds, including danaparoid, dalteparin, enoxaparin, nadroparin, tinzaparin.

Trial Design

Multicenter, randomized, double-blind, and dummy-controlled trial of 449 patients.

Patient Involvement

Patients were randomized to receive dalteparin 100 IU/kg subcutaneously twice a day) and placebo or aspirin (160 mg every day).


Type Measure Time Frame Safety Issue
Primary Ischemic stroke recurrence during first 14 days of treatment.
Secondary Symptomatic cerebral hemorrhage, symptomatic and asymptomatic cerebral hemorrhage, progression of symptoms within first 48 hours, death and functional outcome.